<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920968</url>
  </required_header>
  <id_info>
    <org_study_id>20-NIO-0002</org_study_id>
    <nct_id>NCT04920968</nct_id>
  </id_info>
  <brief_title>Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 OVERALL</brief_title>
  <acronym>PALG ALL7</acronym>
  <official_title>Efficacy and Safety of Obinutuzumab Versus Rituximab in Combination With Chemotherapy for Adult Patients With Newly Diagnosed CD20-positive Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria Sklodowska-Curie Institute - Oncology Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KCRI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maria Sklodowska-Curie Institute - Oncology Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, prospective, randomized and controlled study to compare the efficacy and&#xD;
      safety of obinutuzumab and rituximab in adult ALL patients with CD20 expression.Study&#xD;
      population is 124 patients (62 in each study group).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients achieving complete remission with Minimal Residual Disease level &lt;0.1% of bone marrow cells after one course of induction treatment.</measure>
    <time_frame>assessed between days 33-34 since start of Induction I</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients achieving complete remission with Minimal Residual Disease level &lt;0.01% of bone marrow cells after consolidation.</measure>
    <time_frame>assessed between days 20-28 since start of last course of consolidation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete remission rate after Induction I</measure>
    <time_frame>assessed between days 33-34 since start of Induction I</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall complete remission</measure>
    <time_frame>in 24month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of overall survival</measure>
    <time_frame>in 24 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of relapse-free survival</measure>
    <time_frame>in 24 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of event-free survival</measure>
    <time_frame>in 24 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>in 24 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>in 24 month follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>CD20-positive Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Obinutuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in reference arm (Arm A) will receive rituximab. Patients in experimental arm (Arm B) will receive obinutuzumab instead of rituximab in the same time-points.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in reference arm (Arm A) will receive rituximab. Patients in experimental arm (Arm B) will receive obinutuzumab instead of rituximab in the same time-points.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Chemotherapy will be conducted according to PALG ALL7 protocol, which is considered a standard of care in Poland. Patients in experimental arm will receive obinutuzumab .Obinutuzumab: 1000 mg i.v. (first infusion divided into 100 mg on d. 1 and 900 mg on d. 2).</description>
    <arm_group_label>Obinutuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Chemotherapy will be conducted according to PALG ALL7 protocol, which is considered a standard of care in Poland.The protocol includes the use of rituximab in combination chemotherapy. Rituximab: 375 mg/m2 intravenously (i.v.)</description>
    <arm_group_label>Rituximab</arm_group_label>
    <other_name>Activ comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years.&#xD;
&#xD;
          2. Newly diagnosed Acute lymphoblastic leukemia with CD20 expression on at least 20% of&#xD;
             blasts.&#xD;
&#xD;
          3. Signed written informed consent.&#xD;
&#xD;
          4. Adequate contraception in case of women with child-bearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lymphoblastic lymphoma with bone marrow blasts&lt;20%.&#xD;
&#xD;
          2. Patients with a history of chronic myeloid leukemia or other myeloproliferative&#xD;
             disease.&#xD;
&#xD;
          3. Major surgery within 4 weeks before enrollment.&#xD;
&#xD;
          4. Impaired cardiac function: ejection fraction &lt;40% on echocardiography, QTc interval &gt;&#xD;
             450 ms on baseline electrocardiogram. Myocardial infarction within 6 months prior to&#xD;
             starting study; other clinically significant heart disease (e.g. unstable angina,&#xD;
             congestive heart failure or uncontrolled hypertension, uncontrolled arrhythmias).&#xD;
&#xD;
          5. Active infection e.g. hepatitis B virus, hepatitis C virus, human immunodeficiency&#xD;
             virus&#xD;
&#xD;
          6. Other concurrent severe and/or uncontrolled medical conditions: patients with another&#xD;
             primary malignant disease, except those that do not currently require treatment; acute&#xD;
             or chronic liver, pancreatic or severe renal disease; another severe and/or&#xD;
             life-threatening medical disease.&#xD;
&#xD;
          7. Serum creatinine &gt; 2 times the upper normal limit of the laboratory, total bilirubin&gt;&#xD;
             2.5 upper normal limit unless related to Acute lymphoblastic leukemia, aspartate&#xD;
             aminotransferase or alanine aminotransferase &gt; 5 upper normal limit, unless related to&#xD;
             Acute lymphoblastic leukemia&#xD;
&#xD;
          8. Intolerance to treatment with monoclonal antibody.&#xD;
&#xD;
          9. Positive pregnancy test (beta human chorionic gonadotropin) for women of childbearing&#xD;
             age.&#xD;
&#xD;
         10. Inability to obtain written informed consent.&#xD;
&#xD;
         11. Inability to comply with regular monitoring.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sebastian Giebel, prof. dr n.med.</last_name>
    <phone>32 278 85 23</phone>
    <email>Sebastian.Giebel@io.gliwice.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinika Hematologii z Pododziałem Chorób Naczyń Uniwersyteckiego</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Jarosław Piszcz, Dr heb.med.</last_name>
      <phone>85 831 82 30</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oddział Hematologii Onkologicznej Podkarpacki Ośrodek Onkologiczny</name>
      <address>
        <city>Brzozów</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Jacek Krzanowski, dr n.med</last_name>
      <phone>13 4309728</phone>
      <email>hematologia-sek@szpital-brzozow.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii i Transplantologii Gdańskiego Uniwersytetu Medycznego</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Witold Prejzner, Dr n.med.</last_name>
      <phone>58 349 22 30</phone>
      <email>wpre@gumed.edu.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Transplantacji Szpiku i Onkohematologii Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Oddział w Gliwicach</name>
      <address>
        <city>Gliwice</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Sebastian Giebel, prof. n.med.</last_name>
      <email>Sebastian.Giebel@io.gliwice.pl</email>
    </contact>
    <contact_backup>
      <last_name>Martyna Palich</last_name>
      <phone>tel: 32 278 85 23</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii i Transplantacji Szpiku, Samodzielny Publiczny Szpital Kliniczny</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Grzegorz Helbig, Prof. dr hab. n. med</last_name>
      <phone>32 2591 281</phone>
      <email>ohits@spskm.katowice.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii i Transplantacji Szpiku, Świętokrzyskie Centrum Onkologii</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Ewa Sierlecka, lek.med.</last_name>
      <phone>41 367 4841</phone>
      <email>hematologia@onkol.kielce.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii Collegium Medicum Uniwersytetu Jagiellońskiego</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Tomasz Sacha, Prof. dr hab.n.med.</last_name>
      <phone>12 424 76 32</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oddział Hematologiczny Wojewódzkiego Szpitala Specjalistycznego w Legnicy</name>
      <address>
        <city>Legnica</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Jadwiga Hołojda, Dr n. med.</last_name>
      <phone>505 149 579</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Hematoonkologii I Transplantacji Szpiku, Uniwersytet Medyczny w Lublinie</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Marek Hus, Prof.dr hab.n.med.</last_name>
      <phone>81 53 45 468</phone>
      <email>marekhus@umlub.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oddział Kliniczny Hematologii Samodzielnego Publicznego Zakładu Opieki Zdrowotnej MSWiA z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie</name>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Janusz Hałka, dr n.med.</last_name>
      <phone>89 539 81 30</phone>
      <email>ord.hematologia@poliklinika.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii i Chorób Rozrostowych Układu Krwiotwórczego Uniwersytetu Medycznego w Poznaniu</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Lidia Gil, Prof. dr hab. n. med.</last_name>
      <phone>61 854 93 83</phone>
      <email>hematologia.sekretariat@skpp.edu.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii, Kliniczny Szpital Wojewódzki nr 1</name>
      <address>
        <city>Rzeszów</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Mirosław Markiewicz, Prof.dr hab.n.med</last_name>
      <phone>17 86 66 609</phone>
      <email>m.markiewicz@szpital.rzeszow.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii Pomorskiego Uniwersytetu Medycznego</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Barbara Zdziarska, Prof.dr hab.n.med.</last_name>
      <phone>091 4253347</phone>
      <email>sekr.hemat@spsk1.szn.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oddział Hematologii, Specjalistyczny Szpital Miejski</name>
      <address>
        <city>Toruń</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Edyta Cichocka, Dr n.med.</last_name>
      <phone>56 61 00 411</phone>
      <email>hematologia@med.torun.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Chorób Wewnętrznych i Hematologii Wojskowy Instytut Medyczny</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Piotr Rzepecki, Prof. dr hab. n. med.</last_name>
      <phone>22 261 817 160</phone>
      <email>przepecki@wim.mil.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii, Instytut Hematologii i Transfuzjologii</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Ewa Lech - Marańda, Prof. dr hab. n. med.</last_name>
      <phone>22 349 63 34</phone>
      <email>hemsek@ihit.waw.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii, Onkologii i Chorób Wewnętrznych Warszawskiego Uniwersytetu Medycznego</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Grzegorz Basak, Prof. dr hab. n. med.</last_name>
      <phone>22 599 28 18</phone>
      <email>kho@spcsk.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Anna Czyż, Dr n.med.</last_name>
      <phone>71 784 25 76</phone>
      <email>khn@usk.wroc.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oddział Hematologiczny Z Oddziałem Nowotworów Krwi Dolnośląskie Centrum Transplantacji Komórkowych Z Krajowym Bankiem Dawców Szpiku</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Jarosław Dybko, dr n.med.</last_name>
      <phone>71 78 313 75</phone>
      <email>jdybko@dctk.wroc.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 25, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

